Methods and materials for treating endometrial cancer by assessing combinations of mutations and expression levels
AssigneesMayo Foundation for Medical Education and Research, University of Iowa Research Foundation
InventorsKarl C. Podratz, Jesus Gonzalez Bosquet
Life of this patent
Estimating the term…
Abstract
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having endometrial cancer. For example, methods and materials for identifying endometrial cancers likely to respond to a particular cancer treatment (e.g., a platinum based cancer therapy) are provided. This document also relates to materials and methods for using one or more cancer treatments to treat a mammal (e.g., a human) identified as likely to respond to a particular cancer treatment.
Claims22
A method for treating a mammal having endometrial cancer, wherein said method comprises:
- (a) detecting (a-i) a mutation in nucleic acid encoding a FBW7 polypeptide or nucleic acid regulating expression of said FBW7 polypeptide, (a-ii) a mutation in nucleic acid encoding a PPP2R1A polypeptide or nucleic acid regulating expression of said PPP2R1A polypeptide, and (a-iii) an increased level of expression of nucleic acid encoding a CCNA2 polypeptide in a sample obtained from said mammal as compared to the level of expression of nucleic acid encoding said CCNA2 polypeptide in a control sample obtained from a comparable mammal not having endometrial cancer;
- and
- (b) administering a cancer treatment to said mammal, wherein said cancer treatment is not a platinum based cancer therapy.
A method for treating a mammal having endometrial cancer, wherein said method comprises:
- (a) detecting (a-i) an absence of a mutation in nucleic acid encoding a FBW7 polypeptide or nucleic acid regulating expression of said FBW7 polypeptide, (a-ii) an absence of a mutation in nucleic acid encoding a PPP2R1A polypeptide or nucleic acid regulating expression of said PPP2R1A polypeptide, and (a-iii) an absence of an increased level of expression of nucleic acid encoding a CCNA2 polypeptide in a sample obtained from said mammal as compared to the level of expression of nucleic acid encoding said CCNA2 polypeptide in a control sample obtained from a comparable mammal not having endometrial cancer;
- and
- (b) administering a platinum based cancer therapy to said mammal.
A method for treating a mammal having endometrial cancer, wherein said method comprises:
- (a) detecting (a-i) a mutation in nucleic acid encoding a FBW7 polypeptide or nucleic acid regulating expression of said FBW7 polypeptide, (a-ii) a mutation in nucleic acid encoding a PPP2R1A polypeptide or nucleic acid regulating expression of said PPP2R1A polypeptide, and (a-iii) an increased level of expression of nucleic acid encoding a CIP2A polypeptide in a sample obtained from said mammal as compared to the level of expression of nucleic acid encoding said CIP2A polypeptide in a control sample obtained from a comparable mammal not having endometrial cancer;
- and
- (b) administering a cancer treatment to said mammal, wherein said cancer treatment is not a platinum based cancer therapy.
A method for treating a mammal having endometrial cancer, wherein said method comprises:
- (a) detecting (a-i) an absence of a mutation in nucleic acid encoding a FBW7 polypeptide or nucleic acid regulating expression on of said FBW7 polypeptide, (a-ii) an absence of a mutation in nucleic acid encoding a PPP2R1A polypeptide or nucleic acid regulating expression of said PPP2R1A polypeptide, and (a-iii) an absence of an increased level of expression of nucleic acid encoding a CIP2A polypeptide in a sample obtained from said mammal as compared to the level of expression of nucleic acid encoding said CIP2A polypeptide in a control sample obtained from a comparable mammal not having endometrial cancer;
- and
- (b) administering a platinum based cancer therapy to said mammal.
Dependencies are inferred from the claim text.